Terminator3D/iStock via Getty Images
Blockbuster weight loss medications from Novo Nordisk (NVO) and Eli Lilly (NYSE:LLY) lead Evaluate Pharma’s list of best-selling drugs projected for 2025 after the incretins pushed Bristol Myers’ (BMY) cancer medication Opdivo from the 10-product list.
The GLP-1s semaglutide and
